Julia A Zhang1, Sandi A Kwee2, Linda L Wong1. 1. Department of Surgery, University of Hawaii School of Medicine, Honolulu, HI 96813, United States. 2. The Queens Medical Center, Honolulu, HI 96813, United States.
Abstract
AIMS: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and liver transplant (LT) prolongs survival. However, 15-20% will experience recurrent HCC, most occurring within 2 years of LT. HCC patients with late recurrences (>5 years after LT) may have distinctive clinical/biological characteristics. METHODS: A retrospective review was conducted of 88 patients who underwent LT for HCC between 1993-2015, analyzing demographics, clinical factors, explant pathology, and outcome. RESULTS: Median follow-up was 6.4 years. HCC recurred in 15 (17.0%) patients with mean time to recurrence of 3.96 +/- 3.99 years. Five patients recurred >5 years post-LT. All late recurrences involved males in their 50s, recurring at 8.5 years on average. Recurrences occurred in chest wall (2), liver (2), lung (2), bone (1) and pelvis (1), with multifocal involvement in 2 patients. Four patients died within 18 months of late recurrence. The fifth patient is alive after ablation of liver recurrence and treatment with sorafenib and everolimus. CONCLUSIONS: One-third of post-LT patients with recurrent HCC experienced late recurrence. Although the sample size makes it difficult to identify significant risk factors, this study highlights the importance of long-term follow up and need for biomarkers to identify patients at risk for late recurrences.
AIMS: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and liver transplant (LT) prolongs survival. However, 15-20% will experience recurrent HCC, most occurring within 2 years of LT. HCCpatients with late recurrences (>5 years after LT) may have distinctive clinical/biological characteristics. METHODS: A retrospective review was conducted of 88 patients who underwent LT for HCC between 1993-2015, analyzing demographics, clinical factors, explant pathology, and outcome. RESULTS: Median follow-up was 6.4 years. HCC recurred in 15 (17.0%) patients with mean time to recurrence of 3.96 +/- 3.99 years. Five patients recurred >5 years post-LT. All late recurrences involved males in their 50s, recurring at 8.5 years on average. Recurrences occurred in chest wall (2), liver (2), lung (2), bone (1) and pelvis (1), with multifocal involvement in 2 patients. Four patients died within 18 months of late recurrence. The fifth patient is alive after ablation of liver recurrence and treatment with sorafenib and everolimus. CONCLUSIONS: One-third of post-LT patients with recurrent HCC experienced late recurrence. Although the sample size makes it difficult to identify significant risk factors, this study highlights the importance of long-term follow up and need for biomarkers to identify patients at risk for late recurrences.
Authors: Linda L Wong; Brenda Hernandez; Sandi Kwee; Cheryl L Albright; Gordon Okimoto; Naoky Tsai Journal: Am J Surg Date: 2012-01-09 Impact factor: 2.565
Authors: J F Castroagudín; E Molina-Pérez; R Ferreiro-Iglesias; I Abdulkader; E Otero-Antón; S Tomé; E Varo-Pérez Journal: Transplant Proc Date: 2012 Jul-Aug Impact factor: 1.066
Authors: L Marelli; A Grasso; M Pleguezuelo; H Martines; R Stigliano; A P Dhillon; D Patch; B R Davidson; D Sharma; K Rolles; A K Burroughs Journal: Ann Surg Oncol Date: 2008-09-06 Impact factor: 5.344
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Cem Simsek; Amy Kim; Michelle Ma; Nilay Danis; Merve Gurakar; Andrew M Cameron; Benjamin Philosophe; Jacqueline Garonzik-Wang; Shane Ottmann; Ahmet Gurakar; Behnam Saberi Journal: Hepatoma Res Date: 2020-03-20